ReviewWorld journal of biological chemistry2015
Inflammation, oxidative stress and renin angiotensin system in atherosclerosis.
Review in World journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 2 syntheses or guidelines pooled it, 305 citations in OpenAlex.
- Adjunctive therapy with lipid-lowering agents in COVID-19: a systematic review and meta-analysis of randomized controlled trials.Lipids in health and disease · 2023Pooled it
- Associations between XRCC1 Gene Polymorphisms and Coronary Artery Disease: A Meta-Analysis.PloS one · 2016Pooled it
- Profiles and Prognostic Value of a Non-Invasive Liver Fibrosis Marker in Patients With Acute and Chronic Coronary Syndrome: Insights From the CLIDAS-PCI.Circulation reports · 2026Article
- Inflammatory and neurotoxic risk of atorvastatin in diabetic peripheral neuropathy: TNF-centered evidence integrating network toxicology, scRNA-Seq, and cell validation.Frontiers in chemistry · 2026Article
- Exploring Mechanisms of Ephx2 in Treating Atherosclerosis Using Independent Cascade Model and Adverse Outcome Pathways.Combinatorial chemistry & high throughput screening · 2026Article
- Metabolically Abnormal Obesity and Carotid Plaque Vulnerability: A Vessel Wall MRI Study Linking Obesity Phenotypes to Atherosclerotic Instability.Arteriosclerosis, thrombosis, and vascular biology · 2025Article
- Angiotensin II and Cardiovascular Disease: Balancing Pathogenic and Protective Pathways.Current issues in molecular biology · 2025Review
- Neural progenitor cell-derived exosomes in ischemia/reperfusion injury in cardiomyoblasts.BMC neuroscience · 2025Article
- J-shaped association of neutrophil-to-lymphocyte ratio with all-cause mortality and linear association with cardiovascular mortality in stroke survivors.Frontiers in neurology · 2025Article
- Correlation between α-ketoglutarate and the oxidative stress response in patients with coronary heart disease and prognostic analysis of interventional therapy for coronary heart disease.Frontiers in cardiovascular medicine · 2025Article
- Longitudinal TyG-BMI trajectories predict carotid atherosclerosis progression in a Chinese retrospective cohort.Frontiers in cardiovascular medicine · 2025Article
- Natural, Engineered, and Hybrid Platelet Membrane-Based Nanotherapeutics for Inflammatory Diseases.International journal of nanomedicine · 2025Review
- Prognostic Value of Glucose-to-Potassium Ratio in Acute Ischemic Stroke Patients Undergoing Thrombolysis and Its Interaction with Inflammation.Clinical interventions in aging · 2025Article
- A retrospective cross-sectional study of association between triglyceride-glucose index and carotid atherosclerosis.Frontiers in cardiovascular medicine · 2025Article
- Rapid FEV1 decline and the effects of both FEV1 and FVC on cardiovascular disease: A UK biobank cohort analysis.BMC public health · 2024Article
- Exploring Angiotensin II and Oxidative Stress in Radiation-Induced Cataract Formation: Potential for Therapeutic Intervention.Antioxidants (Basel, Switzerland) · 2024Review
- The Emerging Specialty of Cardio-Rheumatology.Current atherosclerosis reports · 2024Review
- Possible role of LCZ696 in atherosclerosis: new inroads and perspective.Molecular and cellular biochemistry · 2024Review
- Aprotinin (I): Understanding the Role of Host Proteases in COVID-19 and the Importance of Pharmacologically Regulating Their Function.International journal of molecular sciences · 2024Review
- Vascular Response of Triiodothyronine on Isolated Aortic Rings: Contribution of Redox Mechanisms.Arquivos brasileiros de cardiologia · 2024Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is a chronic inflammatory disease associated with cardiovascular dysfunction including myocardial infarction, unstable angina, sudden cardiac death, stroke and peripheral thromboses. It has been predicted that atherosclerosis will be the primary cause of death in the world by 2020. Atherogenesis is initiated by endothelial injury due to oxidative stress associated with cardiovascular risk factors including diabetes mellitus, hypertension, cigarette smoking, dyslipidemia, obesity, and metabolic syndrome. The impairment of the endothelium associated with cardiovascular risk factors creates an imbalance between vasodilating and vasoconstricting factors, in particular, an increase in angiotensin II (Ang II) and a decrease in nitric oxide. The renin-angiotensin system (RAS), and its primary mediator Ang II, also have a direct influence on the progression of the atherosclerotic process via effects on endothelial function, inflammation, fibrinolytic balance, and plaque stability. Anti-inflammatory agents [statins, secretory phospholipase A2 inhibitor, lipoprotein-associated phospholipase A2 inhibitor, 5-lipoxygenase activating protein, chemokine motif ligand-2, C-C chemokine motif receptor 2 pathway inhibitors, methotrexate, IL-1 pathway inhibitor and RAS inhibitors (angiotensin-converting enzyme inhibitors)], Ang II receptor blockers and ranin inhibitors may slow inflammatory processes and disease progression. Several studies in human using anti-inflammatory agents and RAS inhibitors revealed vascular benefits and reduced progression of coronary atherosclerosis in patients with stable angina pectoris; decreased vascular inflammatory markers, improved common carotid intima-media thickness and plaque volume in patients with diagnosed atherosclerosis. Recent preclinical studies have demonstrated therapeutic efficacy of vitamin D analogs paricalcitol in ApoE-deficient atherosclerotic mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.